CHF 150k · Other round · Healthtech · Zurich, Switzerland
PANDA Therapeutics, a Zurich biotech developing a multi-target antibody approach for Alzheimer’s disease, has reached CHF 150k in Venture Kick support after completing the programme’s Stage III. Venture Kick’s announcement says the backing will help turn the project into a company prepared for manufacturing, regulatory work and pharmaceutical partnerships.
Venture Kick had already announced CHF 40k of support for PANDA on 27 March 2026. The 31 August announcement presents CHF 150k as the Stage III programme milestone, so the headline figure is treated here as cumulative Venture Kick support rather than CHF 150k of entirely new capital.
From scientific concept to partner-ready programme
PANDA is developing an antibody-based therapy intended to address several harmful protein deposits in the brain at once. The company says its candidate is designed to target amyloid-beta and tau, limit the spread of those deposits and help the body clear them. That differs from the single-target framing of current anti-amyloid treatments, although the approach remains headed toward clinical development rather than being a demonstrated treatment.
The commercial plan is built around global pharmaceutical and biotechnology partners. PANDA expects licensing, co-development and commercialisation relationships to carry the programme forward as its lead candidate matures. That makes early technical and organisational evidence part of the product: a potential partner must be able to assess the antibody’s scientific rationale, intellectual property, manufacturability and regulatory path, not only the breadth of its target profile.
CHF 150k funds the development scaffolding
According to Tech.eu’s report, the funding will support company formation, business development, a scientific and clinical advisory board, CMC and manufacturing planning, intellectual-property and regulatory work, and engagement with investors and pharmaceutical groups. Those workstreams do not substitute for preclinical or clinical evidence. They are the infrastructure required to make the programme financeable and partner-ready.
The multi-target thesis gives PANDA a clear point of differentiation, but it also raises the standard of proof. The company will need evidence that addressing several protein deposits produces a useful biological advantage while retaining acceptable specificity, safety and manufacturing characteristics. For a young biotech, the next value-creating milestone is therefore not scale in the conventional software sense; it is a development package that lets specialist investors and pharma partners judge whether the added biological ambition is worth carrying into more expensive studies.
PANDA says the broader platform could eventually address other protein-misfolding diseases, including Parkinson’s disease and systemic amyloidosis. For now, the Alzheimer’s programme is the test of whether that platform logic can be converted into a development asset.
